Efficacy of brodalumab in psoriasis patients with a body weight >100 kg: Real‐world evidence (RWE) from the LIBERO study

Abstract Background Patients with psoriasis often suffer from obesity. However, only limited data are available on the efficacy of brodalumab 210 mg, a fully human monoclonal immunoglobulin IgG2 antibody binding to the human interleukin 17 receptor subunit A, in obese patients in daily practice, to date. Objectives A subgroup analysis from the LIBERO study was conducted to compare the effectiveness of brodalumab in patients weighing ≤100 and >100 kg after ~12 weeks (W) and ~52 W. Methods LIBERO is a large prospective, multicenter, non‐interventional, real‐world‐evidence study including adult patients with plaque psoriasis treated with brodalumab 210 mg. Results Four hundred and sixty‐one patients with a body weight up to 100 kg (nonobese) and 161 patients with >100 kg body weight (obese) were included in this subgroup analysis. At baseline, the majority of patients in both groups had very severe (12.6%; 15.7%) or severe (49.4%; 55.0%) psoriasis, as assessed by Physician Global Assessment (PGA). As of W2, a significant reduction of the mean PASI could be achieved in both groups. In patients weighing ≤100 kg mean PASI decreased from 16.9 to 9.0 and further improved to 2.6 at ~W12 ( p < 0.001). In the patient group >100 kg, the PASI decreased from 17.9 to 10.2 at ~W2 ( p < 0.001) and improved further to 3.9 at ~W12 ( p < 0.001). However, at ~W12 absolute PASI0‐3 rates were lower in patients >100 kg than in patients ≤100 kg (68.4% vs. 80.5%, p = 0.006); there was no statistically significant difference between the groups at ~W52/last visit any more in any of the effectiveness parameters with, for example, a PGA0/1 response of 82.3% versus 86.5% ( p = 0.6089), respectively. Conclusions This subgroup analysis of LIBERO confirmed, that in daily practice brodalumab can be equally beneficial patients with >100 and ≤100 kg in the long‐term management of psoriasis.